Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD01576 ...
Drug Name Dextroamphetamine
Molecular Weight 135.2062
Molecular Formula C9H13N
CAS Number 51-64-9
SMILES C[C@H](N)CC1=CC=CC=C1
External Links
DRUGBANK DB01576
T3DB T3D3051
PubChem Compound 5826
PDR 1511
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Boiling Point 64.7 ℃ 64.7 ℃ [MSDS]
Melting Point -98.0 ℃ -98 ℃ [MSDS]

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Reference
C Max 61.0 ng/ml 61±20 ng/ml PO, oral; Raceme D; extended release formulation; The Pharmacological Basis of Therapeutics
T Max 3.1 h 3.1±1.1 h PO, oral; Raceme D; extended release formulation; The Pharmacological Basis of Therapeutics
Clearance 17.0 L/h 17.0 L/h DRUGBANK
Clearance 0.33 L/h/kg 3.4-7.7 ml/min/kg apparent clearance; PO, oral; adults; The Pharmacological Basis of Therapeutics
Clearance 0.0582 L/h/kg 0.23-1.71 ml/min/kg apparent clearance; PO, oral; adults; The Pharmacological Basis of Therapeutics
Volume of Distribution 195.0 L 195.0 L DRUGBANK
Volume of Distribution 6.1 L/kg 6.11±0.22 L/kg The Pharmacological Basis of Therapeutics
Half-life 11.8 h 11.75 h DRUGBANK
Half-life 16.0 h 16 h post-stroke;  Female, women; DRUGBANK
Half-life 12.4 h 12.4 h post-stroke; Male, men; DRUGBANK
Half-life 7.9 h 7.9 h normal,healthy; DRUGBANK
Half-life 3.9 h 3.5-4.2 h Raceme D/L; PO, oral; adults; Urine alkaline; The Pharmacological Basis of Therapeutics
Half-life 18.0 h 14-22 h Raceme D/L; PO, oral; adults; Uric acid; The Pharmacological Basis of Therapeutics
Half-life 6.8 h 6.8±0.5 h Raceme D; Isomers; Children; The Pharmacological Basis of Therapeutics
Toxicity LD50 96.8 mg/kg 96.8 mg/kg PO, oral; Rattus, Rat; T3DB
Eliminate Route 33.3 % 33.3 % Urinary excretion; DRUGBANK
Eliminate Route 14.5 % 14.5 % Urinary excretion; Raceme D/L; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 24.5 % 23-26 % Raceme D/L; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for children 60.0 mg/day 60 mg/day PO, oral ProCentra dextroamphetamine sulfate PDR
Max dose for children 40.0 mg/day 40 mg/day PO, oral ProCentra dextroamphetamine sulfate PDR
Max dose for adolescents 60.0 mg/day 60 mg/day PO, oral ProCentra dextroamphetamine sulfate PDR
Max dose for adults 60.0 mg/day 60 mg/day PO, oral ProCentra dextroamphetamine sulfate PDR
Max dose for geriatric 60.0 mg/day 60 mg/day PO, oral ProCentra dextroamphetamine sulfate PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1